-
公开(公告)号:US20230082122A1
公开(公告)日:2023-03-16
申请号:US17835418
申请日:2022-06-08
Applicant: Genentech, Inc.
Inventor: Priti HEGDE , Mahrukh HUSENI
IPC: G01N33/574 , A61P35/04 , A61K31/404 , A61K39/395 , A61K45/06 , C07K16/22 , C07K16/28 , C12Q1/6886
Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).
-
公开(公告)号:US20230069966A1
公开(公告)日:2023-03-09
申请号:US17864255
申请日:2022-07-13
Applicant: Genentech, Inc.
Inventor: Michael W. LAIRD , Richard ST. JOHN , Jane V. GUNSON , Kimberly KALEAS , Deepa NADARAJAH , Rachel L.E. ADAMS , Bradley R. SNEDECOR
Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm. The present invention also contemplates a method of producing a recombinant protein comprising (a) fermenting a menE gene-deleted prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, (b) harvesting said recombinant protein; and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm, and wherein the recombinant protein yield is increased by about 20% or greater.
-
公开(公告)号:US20230063741A1
公开(公告)日:2023-03-02
申请号:US17721970
申请日:2022-04-15
Applicant: Genentech, Inc.
Inventor: Justin SCHEER , Wenjun OUYANG , Richard VANDLEN , Philip E. HASS , Eric Gary STEFANICH , Ganesh A. KOLUMAM , Xiaoting WANG , Jed ROSS , Nicholas VAN BRUGGEN , Wyne P. LEE
Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
-
公开(公告)号:US20230047100A1
公开(公告)日:2023-02-16
申请号:US17797293
申请日:2021-01-29
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor: Fillippo ARCADU , Benjamin GUTIERREZ-BECKER , Andreas THALHAMMER , Marco PRUNOTTO , Young Suk OH
Abstract: The application relates to devices and methods for analysing a colonoscopy video or a portion thereof, and for assessing the severity of ulcerative colitis in a subject by analysing a colonoscopy video obtained from the subject. Analysing a colonoscopy video comprises using a first deep neural network classifier to classify image data from the subject colonoscopy video or portion thereof into at least a first severity class (more severe endoscopic lesions) and a second severity class (less severe endoscopic lesions), wherein the first deep neural network has been trained at least in part in a weakly supervised manner using training image data from a plurality of training colonoscopy videos, the training image data comprising multiple sets of consecutive frames from the plurality of training colonoscopy videos, wherein frames in a set have the same severity class label. Devices and methods for providing a tool for analysing colonoscopy videos are also described.
-
145.
公开(公告)号:US20230036463A1
公开(公告)日:2023-02-02
申请号:US17782476
申请日:2020-12-04
Applicant: Genentech, Inc.
Inventor: Qi YANG , Simon S. GAO
Abstract: Embodiments disclosed herein generally relate to predicting geographic-atrophy lesion growth and/or geographic atrophy lesion size in an eye. The predictions can be generated by processing a data object using a neural network. The data object may include a three-dimensional data object representing a depiction of at least part of the eye or a multi-channel data object representing one or more decorresponding pictions of at least part of the eye. The neural network can include a convolutional multi-task neural network that is trained to learn features that are predictive of both lesion-growth and lesion-size outputs.
-
公开(公告)号:US20230028651A1
公开(公告)日:2023-01-26
申请号:US17852227
申请日:2022-06-28
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor: Francis GOSSELIN , Stefan G. KOENIG , Eduardo V. MERCADO-MARIN , Andreas STUMPF , Daniel ZELL , Haiming ZHANG , Stephan BACHMANN , Diane E. CARRERA , Michael E. DALZIEL , Yonghui GE , Jie ZHANG , Raphael BIGLER , Laure Elizabeth Simone FINET , Regis Jean Georges MONDIERE , Yuki NAKAGAWA
IPC: C07D495/04
Abstract: A manufacturing process to a bis-mesylate salt 1b of the pan-RAF inhibitor 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide. The process features a number of efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction to generate thienopyrimidine 2 and a highly chemoselective PtN/C-catalyzed nitro group reduction to access penultimate intermediate 7. The final amide coupling of 7 and 2 was accomplished by a mild and safe protocol employing N,N,N′,N′-tetramethylchloroformamidinium hexafluorophosphate (TCFH) as the coupling reagent, to produce a 1:1 adduct of the freebase and THF. The adduct afforded compound 1b with excellent yield, purity, and form stability on a multikilogram production scale after reaction with MsOH and recrystallization. The methods are able to produce a compound having upwards of 95% purity.
-
公开(公告)号:US20230025980A1
公开(公告)日:2023-01-26
申请号:US17782497
申请日:2020-12-04
Applicant: Genentech, Inc.
Inventor: Michael Gregg KAWCZYNSKI , Jeffrey R. WILLIS , Nils Gustav Thomas BENGTSSON , Jian DAI , Simon Shang GAO
Abstract: Systems and methods relate to processing optical tomography coherence (OCT) images to predict characteristics of a treatment to be administered to effectively treat age-related macular degeneration. The processing can include pre-processing the image by flattening and/or cropping the image and processing the pre-processed image using a neural network. The neural network can include a deep convolutional neural network. An output of the neural network can indicate a predicted frequency and/or interval at which a treatment (e.g., anti-vascular endothelial growth factor therapy) is to be administered so as to prevent leakage of vasculature in the eye.
-
公开(公告)号:US20230016472A1
公开(公告)日:2023-01-19
申请号:US17856912
申请日:2022-07-01
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor: Trung Kien NGUYEN , Quincy WONG , Samaneh ABBASI SURESHJANI , Jacob GILDENBLAT , Yaron ANAVI
IPC: G06V10/774 , G06V10/82 , G06T7/00
Abstract: Described herein are systems, methods, and programming for analyzing and classifying digital pathology images. Some embodiments include receiving whole slide images (WSIs) and dividing each of the WSIs into tiles. For each WSI, a random subset of the tiles may be selected and augmented views of each of the selected tiles may be generated. For each of the selected tiles, a first convolutional neural network (CNN) may be trained to: generate, using a first one of the augmented views corresponding to the selected tile, a first representation of the selected tile, and predict a second representation of the selected tile to be generated by a second CNN, wherein the second representation is generated based on a second one of the augmented views of the selected tile.
-
公开(公告)号:US20230014181A1
公开(公告)日:2023-01-19
申请号:US17842715
申请日:2022-06-16
Applicant: Genentech, Inc.
Inventor: Shirley Sum Yi NG PALACE , Benny CHIH , Reina Angelica Salam BASSIL , Kenneth McCarter SHIELDS
IPC: C12M1/36 , C12N5/0793 , C12M1/32 , C12M1/00 , G01N33/50
Abstract: The present application provides a pluripotent stem cell-derived neuronal culture system for use in modeling neurodegenerative diseases, drug screening and target discovery; and methods of generating homogenous, terminally differentiated neuronal culture from pluripotent stem cells, and compositions resulting thereof; as well as automated cell culture systems that sustain long-term differentiation, maturation and/or growth of neuronal cells for use in modeling neurodegenerative diseases.
-
公开(公告)号:US11555065B2
公开(公告)日:2023-01-17
申请号:US17110969
申请日:2020-12-03
Applicant: Genentech, Inc. , AC Immune SA
Inventor: Oskar Adolfsson , Gai Ayalon , Isidro Hotzel , Danielle Marie Di Cara
IPC: C07K16/18 , G01N33/68 , A61K39/395 , A61K45/06 , A61K39/00
Abstract: The invention provides anti-Tau antibodies and methods of using the same.
-
-
-
-
-
-
-
-
-